Prostate-specific antigen doubling time predicts the efficacy of site-directed therapy for oligoprogressive castration-resistant prostate cancer

Taketo Kawai; Satoru Taguchi; Keina Nozaki; Naoki Kimura; Takahiro Oshina; Takuya Iwaki; Hotaka Matsui; Aya Niimi; Jun Kamei; Yoshiyuki Akiyama; Yuta Yamada; Yusuke Sato; Daisuke Yamada; Tomoyuki Kaneko; Subaru Sawayanagi; Hidetsugu Nakayama; Ryogo Minamimoto; Hideomi Yamashita; Hideyo Miyazaki; Tetsuya Fujimura; Tohru Nakagawa; Haruki Kume

Prostate International (Dec 2023)

Prostate-specific antigen doubling time predicts the efficacy of site-directed therapy for oligoprogressive castration-resistant prostate cancer

Taketo Kawai,
Satoru Taguchi,
Keina Nozaki,
Naoki Kimura,
Takahiro Oshina,
Takuya Iwaki,
Hotaka Matsui,
Aya Niimi,
Jun Kamei,
Yoshiyuki Akiyama,
Yuta Yamada,
Yusuke Sato,
Daisuke Yamada,
Tomoyuki Kaneko,
Subaru Sawayanagi,
Hidetsugu Nakayama,
Ryogo Minamimoto,
Hideomi Yamashita,
Hideyo Miyazaki,
Tetsuya Fujimura,
Tohru Nakagawa,
Haruki Kume

Affiliations

Taketo Kawai: Department of Urology, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan; Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Satoru Taguchi: Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; Corresponding author. Department of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan
Keina Nozaki: Department of Urology, Center Hospital of National Center for Global Health and Medicine, Shinjyuku-ku, Tokyo, Japan
Naoki Kimura: Department of Urology, Center Hospital of National Center for Global Health and Medicine, Shinjyuku-ku, Tokyo, Japan
Takahiro Oshina: Department of Urology, Center Hospital of National Center for Global Health and Medicine, Shinjyuku-ku, Tokyo, Japan
Takuya Iwaki: Department of Urology, Center Hospital of National Center for Global Health and Medicine, Shinjyuku-ku, Tokyo, Japan
Hotaka Matsui: Department of Urology, Center Hospital of National Center for Global Health and Medicine, Shinjyuku-ku, Tokyo, Japan
Aya Niimi: Department of Urology, Center Hospital of National Center for Global Health and Medicine, Shinjyuku-ku, Tokyo, Japan
Jun Kamei: Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Yoshiyuki Akiyama: Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Yuta Yamada: Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Yusuke Sato: Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Daisuke Yamada: Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Tomoyuki Kaneko: Department of Urology, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan
Subaru Sawayanagi: Department of Radiology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Hidetsugu Nakayama: Department of Radiation Oncology, Center Hospital of National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
Ryogo Minamimoto: Department of Radiology, Division of Nuclear Medicine, Center Hospital of National Center for Global Health and Medicine, Shinjyuku-ku, Tokyo, Japan
Hideomi Yamashita: Department of Radiology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Hideyo Miyazaki: Department of Urology, Center Hospital of National Center for Global Health and Medicine, Shinjyuku-ku, Tokyo, Japan
Tetsuya Fujimura: Department of Urology, Jichi Medical University, Shimotsuke-shi, Tochigi, Japan
Tohru Nakagawa: Department of Urology, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan
Haruki Kume: Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan

Journal volume & issue: Vol. 11, no. 4
pp. 239 – 246

Abstract

Read online

Background: In recent years, site-directed therapies (SDTs) targeting progressive lesions in patients with oligometastatic prostate cancer have attracted attention. However, whether they effectively treat oligoprogressive castration-resistant prostate cancer (CRPC) remains unclear. Here, we investigated the efficacy of SDT in patients with oligoprogressive CRPC and identified prognostic factors. Methods: We reviewed 59 patients with oligoprogressive CRPC who underwent SDT targeting prostate or metastatic lesions between April 2014 and March 2022. We evaluated the associations between several pretreatment clinical variables and treatment procedures and a >50% prostate-specific antigen (PSA) response, progression-free survival (PFS), and time to next treatment (TTNT). Results: A PSA response of >50% was observed in 66% of patients. The median PFS and TTNT were 8.3 months and 9.9 months, respectively. Patients with PSA doubling time ≥6 months showed a higher >50% PSA response rate (87% vs. 45%; P 50% PSA response, favorable PFS, and TTNT (P = 0.037, 0.025, and 0.017, respectively). Conclusion: PSA doubling time of ≥6 months may be a key indicator of the favorable efficacy of SDT for oligoprogressive CRPC.

Published in Prostate International

ISSN: 2287-8882 (Print); 2287-903X (Online)
Publisher: Elsevier
Country of publisher: Korea, Republic of
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the genitourinary system. Urology
Website: https://www.sciencedirect.com/journal/prostate-international

About the journal

Abstract

Keywords